News

Opdivo is the first anti PD-1 (programmed death-1) approved to treat previously untreated cases of BRAF V600 wild-type unresectable or metastatic melanoma in adults. The approval was made

The study, RADIANT-4, will be presented at the European Cancer Congress (ECC) 2015 in Vienna, Austria, and was highlighted in the ECC press conference on Saturday, September 26.

Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone is indicated to treat adult patients with multiple myeloma who have received at least one prior therapy. BLINCYTO (blinatumomab) can

Entresto, earlier known as LCZ696, will be available to treat adult patients with symptomatic chronic heart failure and reduced ejection fraction (HfrEF) after final approval from the European

Praluent, which is being developed by Sanofi and Regeneron Pharmaceuticals, will be available in both a 75 mg and 150 mg dose for self-administration every two weeks. It

According to the Centers for Disease Control and Prevention, approximately 21 million people in the United States have been diagnosed with diabetes. Over time, diabetes increases the risk

The Accurin drug candidate is intended at treating solid tumors. The actively targeted Accurin is designed to impart cellular targeting capability. Pfizer’s decision results in a $2.5m payment

MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), an immunomodulatory enzyme, is required for the effective triggering of an immune response. However, dysregulation of MALT1 is also associated

Atlas joins previous seed investors Forbion Capital Partners (Forbion) and Omega Funds (Omega) as investors in this funding round. Replimune, headquartered in Oxford UK and with a significant